Fibrosing interstitial lung diseases: knowns and unknowns
V Cottin, L Wollin, A Fischer… - European …, 2019 - Eur Respiratory Soc
Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, …
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, …
Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis
L Wollin, I Maillet, V Quesniaux, A Holweg… - Journal of Pharmacology …, 2014 - ASPET
The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the treatment
of idiopathic pulmonary fibrosis. To explore its mode of action, nintedanib was tested in …
of idiopathic pulmonary fibrosis. To explore its mode of action, nintedanib was tested in …
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
L Wollin, E Wex, A Pautsch, G Schnapp… - European …, 2015 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterised
by fibrosis of the lung parenchyma and loss of lung function. Although the pathogenic …
by fibrosis of the lung parenchyma and loss of lung function. Although the pathogenic …
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
L Wollin, JHW Distler, EF Redente… - European …, 2019 - Eur Respiratory Soc
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …
phenotype characterised by decline in lung function, worsening quality of life and early …
In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor
DS Bundschuh, M Eltze, J Barsig, L Wollin… - … of Pharmacology and …, 2001 - ASPET
We have investigated the bronchodilator and anti-inflammatory properties of roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-dichloropyrid-4-yl]-benzamide),
a novel, highly …
a novel, highly …
Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke
…, R Beume, M Lucattelli, L Wollin… - American journal of …, 2005 - atsjournals.org
Rationale: There is a need for new agents capable of suppressing the inflammatory response
in chronic obstructive pulmonary disease. Objectives: This study evaluated the effects of …
in chronic obstructive pulmonary disease. Objectives: This study evaluated the effects of …
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
…, K Gelse, O Distler, G Schett, L Wollin… - Annals of the …, 2016 - ard.bmj.com
Background Nintedanib is a tyrosine kinase inhibitor that has recently been shown to slow
disease progression in idiopathic pulmonary fibrosis in two replicate phase III clinical trials. …
disease progression in idiopathic pulmonary fibrosis in two replicate phase III clinical trials. …
Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis
…, CW Chen, O Distler, G Schett, L Wollin… - Annals of the …, 2017 - ard.bmj.com
Background Nintedanib is an inhibitor targeting platelet-derived growth factor receptor,
fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases …
fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases …
[HTML][HTML] BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
FE Herrmann, L Wollin, P Nickolaus - Frontiers in Pharmacology, 2022 - frontiersin.org
The anti-inflammatory and immunomodulatory abilities of oral selective phosphodiesterase
4 (PDE4) inhibitors enabled the approval of roflumilast and apremilast for use in chronic …
4 (PDE4) inhibitors enabled the approval of roflumilast and apremilast for use in chronic …
Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma
Phosphodiesterase (PDE) inhibitors have potential as alternatives or adjuncts to
glucocorticoid therapy in asthma. We compared roflumilast (a selective PDE4 inhibitor) with …
glucocorticoid therapy in asthma. We compared roflumilast (a selective PDE4 inhibitor) with …